IGM Biosciences Inc (OQ:IGMS)

Apr 17, 2024 08:30 am ET
IGM Biosciences Announces Refocusing of Sanofi Collaboration
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM...
Apr 10, 2024 07:00 am ET
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024...
Apr 01, 2024 09:31 am ET
Thinking about buying stock in RPM International, Xilio Therapeutics, KULR Technology, Torrid Holdings, or IGM Biosciences?
NEW YORK, April 1, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RPM, XLO, KULR, CURV, and IGMS.
Mar 07, 2024 04:10 pm ET
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an...
Feb 01, 2024 07:00 am ET
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim...
Jan 03, 2024 07:00 am ET
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare...
Dec 05, 2023 04:01 pm ET
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that it will focus its resources in two strategic areas: (i) treating colorectal cancer using IgM death...
Dec 01, 2023 04:32 am ET
Bulletin from Extraordinary General Meeting in Medivir AB (publ)
STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted. The general meeting was held at Helio GT30 on Grev Turegatan 30 in Stockholm. For more detailed information on the content of the resolution, please see the complete notice of the extraordinary general meeting that is available on the Company's website, www.medivir.com. Minutes from the extraordinary general meeting will be provided on the said website within two weeks from the day of the meeting. The
Nov 21, 2023 01:48 am ET
Medivir to present at the Erik Penser Bank Company Event
STOCKHOLM, Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET.
Nov 13, 2023 04:10 pm ET
IGM Biosciences Announces Third Quarter 2023 Financial Results
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023. “During the third quarter,...
Nov 07, 2023 07:00 am ET
IGM Biosciences to Present at Two Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at two upcoming investor...
Oct 05, 2023 07:29 am ET
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles
Early and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13 of 18 patients with >3 months follow-upDurable clinical benefit, median time to progression (to date) ~4.5 months with >50% of patients still on treatment Consistently good safety and tolerability profileSTOCKHOLM, Oct. 5, 2023 /PRNewswire/ -- Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that all patients in the ongoing phase 2a
Oct 03, 2023 04:05 pm ET
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chairman,...
Sep 06, 2023 07:00 am ET
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the...
Aug 03, 2023 04:10 pm ET
IGM Biosciences Announces Second Quarter 2023 Financial Results
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended June 30, 2023. “We continued to make good...
Jul 03, 2023 04:01 pm ET
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of 1,597,827 shares of its voting common stock and 9,000,000 shares of its non-voting common stock and including the...
Jun 22, 2023 07:58 am ET
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its voting common stock and 7,312,500 shares of its non-voting common stock, in each case at a price to the public...
Jun 21, 2023 05:17 pm ET
IGM Announces Proposed Public Offering and Concurrent Private Placement
IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an...
Jun 02, 2023 05:30 pm ET
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced an update on its clinical development program for IGM-8444, a novel multivalent death receptor 5 (DR5)...
Jun 01, 2023 07:00 am ET
IGM Biosciences to Present at the Jefferies Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the...
May 31, 2023 07:00 am ET
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND)...
May 30, 2023 07:00 am ET
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that it will host a conference call and live webcast to provide an update on its clinical development...
May 12, 2023 09:05 am ET
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on...
May 02, 2023 07:00 am ET
IGM Biosciences to Present at Two Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will present at two upcoming investor conferences: Bank of America Health...
Apr 19, 2023 07:00 am ET
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at...
Apr 13, 2023 04:05 pm ET
IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of six posters at the upcoming American Association for Cancer Research...
Mar 30, 2023 04:05 pm ET
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2022 and...
Mar 27, 2023 07:00 am ET
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday,...
Feb 02, 2023 07:00 am ET
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the...
Jan 17, 2023 07:00 am ET
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-7354, a...
Jan 09, 2023 07:00 am ET
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, and...
Jan 03, 2023 07:00 am ET
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare...
Dec 11, 2022 10:00 am ET
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGM’s expanding portfolio of T cell engagers for hematologic malignancies,...
Dec 01, 2022 07:00 am ET
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of...
Nov 08, 2022 07:00 am ET
IGM Biosciences to Present at Three Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in fireside chats at three upcoming...
Nov 03, 2022 09:05 am ET
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent...
Nov 02, 2022 04:05 pm ET
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they have entered into a clinical trial collaboration and...
Sep 06, 2022 07:00 am ET
IGM Biosciences to Present at Three Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in three upcoming investor conferences in...
Aug 08, 2022 04:10 pm ET
IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent...
Jun 01, 2022 07:00 am ET
IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 Jefferies...
May 10, 2022 07:00 am ET
IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 RBC...
May 09, 2022 04:16 pm ET
IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent...
May 06, 2022 07:00 am ET
IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as...
Apr 06, 2022 04:39 pm ET
IGM Announces Closing of $230.0 Million Public Offering
IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April 1, 2022 of its previously announced underwritten public offering of 8,695,653 shares of its non-voting common stock and, pursuant to the exercise in full by the underwriters...
Mar 30, 2022 12:56 am ET
IGM Announces Pricing of $200.0 Million Public Offering
IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting common stock at a price to the public of $23.00 per share. IGM expects to receive total gross proceeds of...
Mar 29, 2022 07:41 am ET
IGM Announces Proposed Public Offering
IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public...
Mar 29, 2022 06:01 am ET
IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an...
Mar 29, 2022 02:00 am ET
IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with Sanofi
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast today, Tuesday, March 29,...
Feb 09, 2022 07:00 am ET
IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its progress in two Phase 1 clinical trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM...
Feb 03, 2022 04:05 pm ET
IGM Biosciences to Present at the Guggenheim 2022 Oncology Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the Guggenheim 2022...
Jan 05, 2022 07:00 am ET
IGM Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40th Annual J.P....
Dec 11, 2021 01:31 pm ET
IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of clinical results from the Company’s Phase 1 trial evaluating IGM-2323, a...
Dec 08, 2021 07:00 am ET
IGM Biosciences to Collaborate on the Study of IgM and IgA Antibodies for the Prevention of Malaria
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced a grant agreement with the Bill & Melinda Gates Foundation to fund the design, production,...
Dec 06, 2021 04:05 pm ET
IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 63rd Annual ASH Meeting
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 11,...
Nov 10, 2021 04:05 pm ET
IGM Biosciences to Present at the Jefferies London Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Jefferies London Healthcare...
Nov 08, 2021 07:00 am ET
IGM Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Stifel 2021 Virtual Healthcare...
Nov 04, 2021 09:21 am ET
IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the third quarter ended September 30, 2021 and provided an update...
Oct 11, 2021 04:05 pm ET
IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and...
Sep 23, 2021 04:05 pm ET
IGM Biosciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on...
Sep 07, 2021 07:00 am ET
IGM Biosciences to Participate in Three Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in three upcoming investor conferences: Citi 16th Annual...
Aug 09, 2021 04:06 pm ET
IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on...
Jul 29, 2021 05:31 pm ET
IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., as Chief Medical Officer
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical...
Jun 03, 2021 07:01 am ET
IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and P
IGM Biosciences, Inc. (Nasdaq: IGMS) a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the expansion of its IgM antibody platform into infectious diseases, with the anticipated...
May 26, 2021 07:00 am ET
IGM Biosciences to Present at the Jefferies Virtual Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the...
May 12, 2021 07:00 am ET
IGM Biosciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2021...
May 06, 2021 04:07 pm ET
IGM Biosciences Announces First Quarter 2021 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on...
May 03, 2021 08:02 am ET
MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders
MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it has filed definitive proxy materials with the U.S. Securities and...
Apr 27, 2021 07:00 am ET
IGM Biosciences to Present at the Truist Securities Life Sciences Summit
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the...
Apr 12, 2021 07:00 am ET
IGM Biosciences Appoints George Gauthier as Chief Commercial Officer
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of George A. Gauthier to the newly created position of Chief Commercial...
Mar 30, 2021 04:17 pm ET
IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2020 and...
Mar 24, 2021 07:00 am ET
IGM Biosciences to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 30, 2021
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2020 financial results on Tuesday, March...
Mar 15, 2021 07:00 am ET
IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer
IGM Biosciences, Inc. (IGM), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Lisa L. Decker, Ph.D., to the newly created position of Chief Business Officer. Ms....
Feb 05, 2021 07:00 am ET
IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the...
Jan 11, 2021 06:00 pm ET
IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant
IGM Biosciences, Inc. (Nasdaq: IGMS) today announced that it has entered into an exclusive license agreement with Medivir AB (Nasdaq Stockholm: MVIR), through which IGM will receive global, exclusive development and commercialization rights for...
Jan 07, 2021 07:00 am ET
IGM Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 39th Annual J.P. Morgan...
Dec 11, 2020 04:05 pm ET
IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares of its common stock, which includes the exercise of the underwriters’ option to purchase additional shares in...
Dec 08, 2020 10:30 pm ET
IGM Announces Pricing of Upsized $200 million Public Offering
IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common stock at a price to the public of $90.00 per share and, to certain investors in lieu of common stock,...
Dec 07, 2020 05:07 pm ET
IGM Announces Proposed Public Offering
IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $150 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common...
Dec 05, 2020 01:30 pm ET
IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of preliminary clinical results from the Company’s Phase 1 trial evaluating...
Nov 30, 2020 07:00 am ET
IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 62nd Annual ASH Meeting
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 5,...
Nov 23, 2020 07:00 am ET
IGM Biosciences to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, has participated in a fireside chat in advance...
Nov 09, 2020 07:00 am ET
IGM Biosciences to Present at Three Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at three upcoming investor...
Nov 05, 2020 07:02 am ET
IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update
- Initial Data from Phase 1 Trial of IGM-2323 in Relapsed/refractory Non-Hodgkin’s Lymphoma to be Presented at the 62nd American Society of Hematology Annual Meeting and Exposition in December - - First-in-Human Clinical Trial of IGM-8444 for the...
Nov 04, 2020 09:19 am ET
IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it expects the first clinical data from its Phase 1 trial evaluating IGM-2323 will be...
Sep 30, 2020 07:00 am ET
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’s Lymphoma
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-8444, an...
Sep 24, 2020 04:01 pm ET
AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration
AbCellera and IGM Biosciences, Inc. (Nasdaq: IGMS), announced today that they have entered into a multi-year, multi-target strategic research collaboration and license agreement to facilitate the discovery and development of novel IgM antibodies....
Sep 02, 2020 07:00 am ET
IGM Biosciences to Present at Four Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at four upcoming investor...
Aug 06, 2020 04:08 pm ET
IGM Biosciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second quarter ended June 30, 2020 and provided an update on...
Aug 04, 2020 07:00 am ET
IGM Biosciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 Wedbush PacGrow...
May 28, 2020 07:00 am ET
IGM Biosciences to Present at the Jefferies 2020 Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the Jefferies 2020 Healthcare...
May 12, 2020 07:00 am ET
IGM Biosciences to Present at the 2020 RBC Capital Markets Global Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 RBC Capital Markets...
May 07, 2020 04:03 pm ET
IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2020 and provided an update on...
Apr 29, 2020 04:05 pm ET
Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19
Atreca, Inc. (Nasdaq: BCEL), BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), and IGM Biosciences, Inc. (Nasdaq: IGMS), today announced their plans to collaborate to help address the COVID-19 pandemic. The companies will leverage their combined...
Apr 03, 2020 07:00 am ET
IGM Biosciences to Participate in Canaccord Genuity Horizons in Oncology Virtual Event
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a panel discussion on...
Mar 26, 2020 04:05 pm ET
IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2019 and...
Mar 19, 2020 07:00 am ET
IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2019 financial results on Thursday, March...
Mar 04, 2020 07:00 am ET
IGM Biosciences to Present at Two Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that members of the management team will present at two upcoming investor conferences:...
Feb 06, 2020 07:00 am ET
IGM Biosciences to Present at Two Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at two upcoming investor conferences:...
Jan 07, 2020 07:00 am ET
IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis
IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced the appointment of Eric Humke, M.D., Ph.D., to the newly created position of Vice President, Clinical...
Nov 12, 2019 07:00 am ET
IGM Biosciences to Present at Three Upcoming Investor Conferences
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced that Fred Schwarzer, Chief Executive Officer, will...
Nov 07, 2019 05:04 pm ET
IGM Biosciences Announces Third Quarter 2019 Financial Results
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced its financial results for the third quarter ended...
Oct 02, 2019 07:00 am ET
IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma
IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced that the first patient has been dosed in its Phase 1 clinical trial...
Sep 20, 2019 04:05 pm ET
IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the closing of its initial public offering of 12,578,125 shares of its common stock at a price to the public of $16.00 per share, which includes the exercise in full by the underwriters of their...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.